Semaglutide

Semaglutide research peptide in Thailand

Semaglutide is a long-acting GLP-1 receptor agonist — an acylated 31-residue analogue of human glucagon-like peptide-1, developed by Novo Nordisk and marketed clinically as Ozempic and Wegovy — studied for appetite regulation, glycaemic control, and cardiometabolic endpoints. Its roughly week-long half-life made it the reference single-receptor incretin compound against which the newer dual and triple agonists are measured.

Supplied as a lyophilised powder for laboratory research use only. This page summarises published literature so a researcher can identify and characterise the compound; it is not a medicine and gives no administration guidance.

Quick facts

Product

Semaglutide (lyophilised research powder)

Developer

Novo Nordisk (marketed as Ozempic / Wegovy)

CAS number

910463-68-2

Molecular weight

~4113.6 Da

Structure

GLP-1(7-37) backbone with Aib at position 8, Arg34 substitution, and a C18 diacid chain acylated to Lys26 via a spacer

Intended use

laboratory research use only

How semaglutide works

Semaglutide is a GLP-1 analogue engineered for persistence. Two modifications do the work: an aminoisobutyric acid substitution at position 8 blocks cleavage by DPP-4, the enzyme that clears native GLP-1 within minutes, and a C18 fatty diacid chain attached through a spacer to lysine 26 binds reversibly to serum albumin. Albumin binding creates a circulating depot that releases the peptide slowly, stretching the half-life from roughly two minutes for native GLP-1 to about a week.

Once in circulation it engages GLP-1 receptors in three tissue compartments. In pancreatic beta cells it potentiates glucose-dependent insulin secretion while suppressing glucagon release from alpha cells, so the glycaemic effect scales with ambient glucose rather than driving it downward indiscriminately. In the gastrointestinal tract it slows gastric emptying. In the hypothalamus and hindbrain it activates central satiety circuits that reduce food intake. The combination of reduced intake and improved glucose handling is the mechanism behind the metabolic and body-weight findings reported in its trial programme.

Key research findings

• In the STEP-1 phase 3 trial (1,961 adults with overweight or obesity, 68 weeks), the 2.4 mg once-weekly group showed a mean body-weight change of −14.9% versus −2.4% for placebo, with 86.4% reaching at least 5% reduction (Wilding et al., NEJM 2021, PMID 33567185).
• In SUSTAIN-6 (3,297 adults with type 2 diabetes, 104 weeks), the primary composite cardiovascular endpoint occurred in 6.6% of the semaglutide arm versus 8.9% of placebo, meeting the trial's non-inferiority hypothesis; a higher rate of retinopathy complications was also recorded (Marso et al., NEJM 2016, PMID 27633186).
• In SELECT (17,604 participants with obesity and cardiovascular disease but without diabetes), the composite of cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke occurred in 6.5% of the semaglutide arm versus 8.0% of placebo (hazard ratio 0.80, 95% CI 0.72–0.90); adverse events led to discontinuation in 16.6% versus 8.2% (Lincoff et al., NEJM 2023, PMID 37952131).

Research applications

• GLP-1 receptor pharmacology, binding kinetics, and receptor-desensitisation studies.
• Appetite regulation and hypothalamic satiety signalling models.
• Glycaemic control, insulin secretion, and pancreatic beta-cell function research.
• Cardiometabolic risk-marker studies in metabolic disease models.
• Hepatic lipid metabolism and steatotic liver disease (MASLD/NAFLD) investigations.
• Comparator arm for dual and triple incretin agonists in head-to-head pharmacology work.
• Central GLP-1 receptor research in neuroinflammation and neuroprotection models.

Dosing in the literature

Trials escalated across that range in roughly 4-week steps, from 0.25 mg to 2.4 mg. These figures report the escalation schedules used in the published STEP and SUSTAIN programmes — the SUSTAIN trials studied doses up to 1 mg weekly for glycaemic endpoints, and the STEP trials escalated to 2.4 mg weekly for body-weight endpoints. They are provided for literature reference only, not as administration guidance. To model concentrations and volumes for a study, use the peptide calculator.

Reconstitution & storage

Solvent

Bacteriostatic water — the common laboratory choice

Mixing

Add solvent down the vial wall and swirl gently until dissolved; do not shake

Storage

Refrigerate at 2–8 °C after reconstitution

Use within

About 28 days once reconstituted

Freeze / light

Keep lyophilised powder frozen or refrigerated; protect from direct light; avoid repeated freeze–thaw

These are standard laboratory handling conventions, not instructions for use. See bacteriostatic water for the standard diluent. In Thailand's heat and humidity, minimise time at ambient temperature and limit courier exposure to heat.

Selected research

• Once-Weekly Semaglutide in Adults with Overweight or Obesity — New England Journal of Medicine, 2021 (PMID 33567185).
• Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes — New England Journal of Medicine, 2016 (PMID 27633186).
• Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes — New England Journal of Medicine, 2023 (PMID 37952131).
• Further indexed literature via PubMed search for semaglutide.

Related compounds

• Retatrutide — triple GLP-1 / GIP / glucagon agonist; the far end of the incretin family and the usual comparison point for receptor-coverage studies. Tirzepatide (dual GLP-1 / GIP) sits between the two but is not currently in our catalog.
• Bacteriostatic water — the standard diluent used to reconstitute lyophilised research peptides.

See also: retatrutide vs semaglutide vs tirzepatide and more incretin-receptor compounds.

Semaglutide FAQ

Compliance note

Semaglutide is provided for laboratory research use only. It is not intended for human or veterinary use, and it is not intended to diagnose, treat, cure, or prevent any disease. Trial results described on this page are findings of the specific cited studies, not claims about this product.